










Table S1: Baseline characteristics of excluded compared with included HIV-1+ and HIV-2+ patients. 
 HIV-1 (N=66, 483) HIV-2 (N=243) 
Excluded Included Pa Excluded Included Pa 




N =58   
N =185 
Median age in years (IQR) 38 (32;45) 37 (31;44) <0.0001 43 (34;53) 46 (36;52) 0.2862 
Sex, n (%)     <0.0001     0.0539 
   Male 24518 (67.6) 22052 (72.9)  22 (37.9) 97 (52.4)  
   Female 11724 (32.3) 8179 (27.1)  36 (62.1) 88 (47.6)  
   Unknown 10 (0)         
Geographic origin, n (%)     <0.0001     0.6340 
   Africa 6281 (17.3) 2495 (8.3)  45 (77.6) 130 (70.3)  
   Europe 7248 (20.0) 16517 (54.6)  12 (20.7) 47 (25.4)  
   Asia 310 (0.9) 413 (1.4)    2 (1.1)  
   Unknown/Other 22413 (61.8) 10806 (35.7)  1 (1.7) 6 (3.2)  
Transmission risk group, n (%)     <0.0001     0.3513 
   Homo/bisexual male 10574 (29.2) 11825 (39.1)  2 (3.4) 7 (3.8)  
   Injecting drug user 4601 (12.7) 4887 (16.2)  1 (1.7) 2 (1.1)  
   Heterosexual  16831 (46.4) 10783 (35.7)  50 (86.2) 154 (83.2)  
   Mother-to-child 99 (0.3) 26 (0.1)  1 (1.7)    
   Unknown/Other 4147 (11.4) 2710 (9.0)  4 (6.9) 22 (11.9)  
Prior AIDS diagnosis n (%) 8743 (24.1) 7169 (23.7) 0.2250 10 (17.2) 42 (22.7) 0.3762 
cART regimen, n (%)     <0.0001     0.4099 
   2 NRTIs + 1PI/rtv  7541 (20.8) 6823 (22.6)  8 (13.8) 44 (23.8)  
   2 NRTIs + LPV/rtv or DRV/rtv  11048 (30.5) 11039 (36.5)  30 (51.7) 79 (42.7)  
   3 NRTIs 4547 (12.5) 2180 (7.2)  8 (13.8) 24 (13.0)  
   Other combinations 13116 (36.2) 10189 (33.7)  12 (20.7) 38 (20.5)  
Period of cART initiation, n (%)     <0.0001     0.6214 
   1998-1999 7883 (21.7) 6292 (20.8)  4 (6.9) 13 (7.0)  
   2000-2001 5476 (15.1) 3708 (12.3)  5 (8.6) 19 (10.3)  
   2002-2003 5921 (16.3) 3810 (12.6)  6 (10.3) 32 (17.3)  
   2004-2005 5519 (15.2) 4613 (15.3)  16 (27.6) 34 (18.4)  
   2006-2007 5835 (16.1) 5557 (18.4)  11 (19.0) 44 (23.8)  
   2008-2009 5064 (14.0) 5102 (16.9)  10 (17.2) 30 (16.2)  
   2010-2011 554 (1.5) 1149 (3.8)  6 (10.3) 13 (7.0)  
Legend: cART: combination ART; LPV, lopinavir; DRV, darunavir, Other combinations: mainly 2 or 3 NRTIs plus an unboosted PI and combinations with an integrase inhibitor.* Patients fulfilling 
inclusion criteria.a Categorical variables were compared between excluded and included patients using Chi-Square tests or Fisher’s tests as appropriate. Quantitative variables (i.e. age) were 
compared using the Wilcoxon-Mann-Withney test between excluded and included patients. 
